Equities Analysts Issue Forecasts for LH Q2 Earnings

Laboratory Co. of America Holdings (NYSE:LH) – William Blair increased their Q2 2025 earnings per share estimates for Laboratory Co. of America in a research note issued to investors on Monday, February 10th. William Blair analyst A. Brackmann now anticipates that the medical research company will post earnings per share of $4.00 for the quarter, up from their prior forecast of $3.92. The consensus estimate for Laboratory Co. of America’s current full-year earnings is $15.96 per share.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%.

Several other brokerages have also commented on LH. Hsbc Global Res upgraded Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 30th. Morgan Stanley increased their price target on Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Barclays dropped their price target on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a research note on Friday, February 7th. Robert W. Baird lifted their target price on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Finally, Piper Sandler upped their price target on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $265.31.

Laboratory Co. of America Price Performance

Shares of LH opened at $241.05 on Thursday. The company has a 50 day moving average of $236.92 and a two-hundred day moving average of $230.55. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. Laboratory Co. of America has a twelve month low of $191.97 and a twelve month high of $258.59. The company has a market cap of $20.16 billion, a price-to-earnings ratio of 27.33, a price-to-earnings-growth ratio of 1.84 and a beta of 1.07.

Institutional Investors Weigh In On Laboratory Co. of America

A number of institutional investors have recently modified their holdings of LH. AMF Tjanstepension AB increased its position in shares of Laboratory Co. of America by 37.0% in the third quarter. AMF Tjanstepension AB now owns 86,026 shares of the medical research company’s stock valued at $19,232,000 after buying an additional 23,221 shares in the last quarter. CWM LLC grew its stake in Laboratory Co. of America by 41.0% in the 3rd quarter. CWM LLC now owns 7,107 shares of the medical research company’s stock valued at $1,588,000 after acquiring an additional 2,068 shares during the period. Exchange Traded Concepts LLC grew its stake in Laboratory Co. of America by 1,962.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 990 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 942 shares during the period. Swedbank AB increased its holdings in Laboratory Co. of America by 12.0% in the 3rd quarter. Swedbank AB now owns 56,884 shares of the medical research company’s stock worth $12,712,000 after acquiring an additional 6,089 shares in the last quarter. Finally, Indiana Trust & Investment Management Co acquired a new position in Laboratory Co. of America during the third quarter worth $136,000. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Der Vaart Sandra D. Van sold 1,000 shares of the firm’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $239.42, for a total transaction of $239,420.00. Following the sale, the executive vice president now owns 2,670 shares in the company, valued at approximately $639,251.40. This trade represents a 27.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Amy B. Summy sold 3,672 shares of Laboratory Co. of America stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $238.91, for a total transaction of $877,277.52. Following the completion of the transaction, the chief marketing officer now directly owns 4,318 shares of the company’s stock, valued at $1,031,613.38. The trade was a 45.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,383 shares of company stock valued at $4,408,373 in the last quarter. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. The ex-dividend date is Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.19%. Laboratory Co. of America’s payout ratio is currently 32.65%.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.